Pfizer acquires Vicuron in $1.9B deal

Biopharma giant Pfizer is paying $1.9 billion to buy Vicuron Pharmaceuticals, a King of Prussia, Pennsylvania-based drug developer with two products under FDA review. The deal for $29.10 per share marks a 74 percent premium over Vicuron's 90-day average stock price, which closed Wednesday at $15.80 and shot up 77 percent in premarket trading. The buyout will put a number of compounds in Pfizer's pipeline, including anidulafungin for fungal infections and dalbavancin for Gram-positive infections. Dalbavancin has shown positive results in Phase III studies in complicated skin and soft tissue infections and in a Phase II study in catheter-related bloodstream infections. The product has once-weekly dosing.

"By acquiring Vicuron, we can help bring two very important new medicines to patients around the world," said Hank McKinnell, chairman and CEO of Pfizer. "This transaction builds on Pfizer's extensive experience in anti-infectives and demonstrates our commitment to strengthen and broaden our pharmaceutical business through strategic product acquisitions."

- read this story from TheStreet.com for more

ALSO: The news boosted shares of Arpida and Basilea, both of which are developing anti-infectives. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.